This study is in progress, not accepting new patients
Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCLA UCSD UCSF
- Dates
- study startedestimated completion
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Puma Biotechnology, Inc.
- Links
- HER Kinase Inhibition in Patients With HER2- And HER3-mutant Cancers Efficacy and Determinants of Response to HER Kinase Inhibition in HER2 -Mutant Metastatic Breast Cancer
- ID
- NCT01953926
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- At least 582 people participating
- Last Updated